N/A N=7 Minimally Invasive Holmium:YAG Laser Blepharoplasty
Lower Eyelid Entropion
Primary: Change in Lower Eyelid Bags. — 5; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=101 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
Hepatitis C Virus (HCV)
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Dosing (SVR12) — 97.0 percentage of participants
N/A N=206 EmergeNcy Department Apneic Oxygenation Versus Usual Care During Rapid Sequence Intubation
Diffuse Apneic Oxygenation
Primary: Mean (Average) Arterial Oxygen Saturation — 92; 93 Percent Saturation (SpO2)
Phase 4 N=151 Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus
Type I Diabetes Mellitus
Primary: Changes in the Mean Value of HbA1c — -0.71; -0.49; -0.66; -0.27 percentage of HbA1c — p=0.019
N/A N=1,836 Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study
Obstructive Sleep Apnea of Adult · Insomnia · Circadian Rhythm Sleep Disorder
Primary: Change in CGCAHPS Global Rating After 12 Months — 8.32; 8.45 units on a scale — p=0.687
Phase 1 N=60 Transition From Alendronate to Romosozumab (AMG 785)
Osteoporosis
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine — 2.13; 2.08 percent change — p=0.002
Phase 2 N=13 Afatinib in NSCLC With HER2 Mutation
NSCLC
Primary: Disease Control (Defined as Complete or Partial Response, or Disease Stabilisation Lasting at Least 12 Weeks) — 7; 6; 4; 5 Participants
Phase 1 N=8 A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Dose Normalized Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Evacetrapib — 111; 248…
Phase 2 N=42 Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Renal Transplant Osteodystrophy
Primary: Bone Mineral Density of Spine at 6 Months — 0.98; 0.97 gm/cm^2
Phase 1 N=27 A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
Type 1 Diabetes Mellitus
Primary: Sleep Respiratory Quotient (RQ) in Type 1 Diabetes Mellitus (T1DM) — 0.822; 0.846 ratio
N/A N=2,482 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
Angioplasty · Chronic Coronary Occlusion · Stent Thrombosis
Primary: Number of Participants With Incidence of the Composite Rate of Cardiac Death and Any Myocardial Infarction (MI) (Including Q-wave and Non-Q-wave) — 33 Participants
Phase 2 N=50 Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Recurrent Merkel Cell Carcinoma · Stage III Merkel Cell Carcinoma AJCC v7 · Stage IIIA Merkel Cell Carcinoma AJCC v7
Primary: Objective Response Rate (ORR) Defined as the Proportion of Patients Who Have Achieved Complete Response (CR) or Partial Response (PR) According to Response Evaluation…
Phase 1 N=17 A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors
Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 1; 2 Participants
N/A N=23 Efficacy of Parent-Child Interaction Therapy With Autism Spectrum Disorder
Noncompliance
Primary: Eyberg Child Behavior Inventory — 132.50; 154.33; 18.9; 19.11 units on a scale
Phase 4 N=27 The Effect of Intravenous Acetaminophen on Post-Operative Pain After Craniotomy
Pain
Primary: Post-operative Opioid Consumption — 228; 312 ug